arrow
T

Thomas Bachelot

centre leon berard
H指数:65
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort

与转移性乳腺癌一线抗HER2为基础治疗中表现出非凡疗效相关的临床特征:来自ESME国家队列的真实世界数据

Breast
IF7.9
2026-10-130
OA
Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database

人表皮生长因子受体2低表达、激素受体阳性转移性乳腺癌的化疗结局:来自法国多中心ESME数据库的见解

Breast
IF7.9
2026-09-270
OA
Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

HER2阴性低表达雌激素和孕激素受体转移性乳腺癌患者的特征和结局:多中心ESME队列研究

2026-05-180
OAAI
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

Datopotamab deruxtecan在未经治疗的晚期三阴性乳腺癌患者中的TROPION-Breast02: 一项随机,开放标签,国际,III期试验

2026-04-030
PRE
PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer

PELICAN-IPC 2015–016/Oncodistinct-003:一项关于帕博利珠单抗联合新辅助化疗治疗HER2阴性炎性乳腺癌的随机非对照II期研究

2026-01-010
OAAI
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort

老年与年轻HR阳性HER2阴性转移性乳腺癌女性患者真实世界多中心法国ESME队列中的近期治疗与生存趋势

2025-12-050
PRE
Remotely supervised online cognitive training to reduce cognitive difficulties following chemotherapy in patients treated for localized breast cancer: Protocol of the Cog-Stim2 multicenter randomized controlled trial

远程监督的在线认知训练以减少局部乳腺癌治疗后化疗患者的认知困难:Cog-Stim2多中心随机对照试验方案

2025-11-130
PRE
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

CDK4/6抑制剂治疗后疾病进展的HR阳性/HER2阴性转移性乳腺癌患者中真实世界的治疗模式与疗效:ESME-MBC队列研究

2025-09-170
PREAI
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial

帕梯他马单抗德鲁克替康在HRHER2+−晚期乳腺癌中的治疗:一项II期临床试验

2025-09-040
OAAI
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature

雌激素受体阳性、HER2阴性且对芳香化酶抑制剂获得性耐药的晚期乳腺癌基因组景观:鉴定与ESR1改变相关的基因特征

2025-06-120
PRE
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
2024-08-020
OA
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

曲妥珠单抗deruxtecan与曲妥珠单抗emtansine治疗HER2-positive转移性乳腺癌: DESTINY-Breast03试验的长期生存分析

2024-06-026
OAAI
Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)
2024-05-020
PRE